Back to discover
§ The cross-read
BMY vs GILD
GILD's Section-2 aggressive Pricing Reform risk is the dominant variable in any cross-read.
Fair-value ladder
Fair-value ladder unavailable — one or both tickers have no published mid fair value.
Aligned scorecards
BMYGILD
| BMYBristol-Myers Squibb Company | GILDGilead Sciences Inc. | |
|---|---|---|
| Trend | - | - |
| Price | - | - |
| Fair value | - | - |
| FV range | - | - |
| Upside | - | - |
| Rating | Manter | Manter |
| Confidence | - | - |
| Moat | - | - |
| Archetype | - | - |
| Sector | Health Care | Health Care |
| Analyzed | - | - |
9-category scorecards
BMY
Bristol-Myers Squibb Company
Valuation
5.0/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
3.5/10
0.11x
Profitability
7.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
5.0/10
0.11x
Competitive Moat
6.5/10
0.11x
Earnings Quality
8.0/10
0.11x
Capital Efficiency
7.5/10
0.11x
Weighted Overall
6.1/10
GILD
Gilead Sciences Inc.
Valuation
5.0/10
0.11x
Management
7.3/10
0.11x
Balance Sheet
6.0/10
0.11x
Profitability
8.5/10
0.11x
Revenue Growth
4.5/10
0.11x
Risk Assessment
7.0/10
0.11x
Competitive Moat
6.5/10
0.11x
Earnings Quality
7.5/10
0.11x
Capital Efficiency
7.5/10
0.11x
Weighted Overall
6.6/10